E-mail

E-mail a Wiley Online Library Link

Joel B. Nelson, Karim Fizazi, Kurt Miller, Celestia Higano, Judd W. Moul, Hideyuki Akaza, Thomas Morris, Stuart McIntosh, Kristine Pemberton and Martin Gleave Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone Cancer 118

Version of Record online: 11 JUL 2012 | DOI: 10.1002/cncr.27674

This large, randomized, placebo-controlled phase 3 trial evaluated the endothelin A receptor antagonist zibotentan in patients with castration-resistant prostate cancer metastatic to bone. Treatment with zibotentan 10 mg/day did not lead to a statistically significant improvement in overall survival in this patient population.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH